Literature DB >> 30280780

HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression.

Z-Y Dong1, Y-R Zhou, L-X Wang.   

Abstract

OBJECTIVE: p38 MAPK are a class of protein kinase that may induce or prevent apoptosis in different circumstance. Emerging researches show that it plays a vital role in tumor progression and therefore understanding its dual role in different stages of lung cancer are important to investigate. Also in this study, we planned to understand its upstream target proteins like HDAC1 and uPAR which are responsible for p38 MAPK activation in the pathway.
MATERIALS AND METHODS: We initially develop lung cancer mice model by exposing them to high nicotine content tobacco smoke. The pathological stages of initial and advanced lung cancer are observed and confirmed through histological sectioning. The expression of HDAC1, uPAR and p38 MAPK are observed and analyzed in different stages of lung cancer using immunohistochemistry and Western blotting.
RESULTS: After 4 and 6 months of regular exposure of high nicotine content smoke, the A/J strain mice develop initial and advanced stage of lung cancer. The initial stage cancer develops thick tissue layers with fibrosis whereas advanced stages of lung cancer show more proliferative cells. The expression of HDAC1 and uPAR shows the minimal expression pattern in control and initial stages of lung cancer, but its expression increased in advanced stage of cancer. In case of phospho-p38 MAPK, mild expression was observed almost in every individual cell in the initial stages of cancer, which implies its protective role in preventing advanced stage of cancer. But in advanced stage of lung cancer, we observed dysregulated overexpression of phospho-p38 MAPK.
CONCLUSIONS: The epigenetic regulation of uPAR by HDAC1 confirms its indirect role in regulating p38 MAPK as tumor progress.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30280780     DOI: 10.26355/eurrev_201809_15932

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

2.  Expression patterns and therapeutic implications of histone deacetylase-1 across carcinomas: a comprehensive molecular docking and MD simulation study.

Authors:  Bader Alshehri
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

3.  Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.

Authors:  Mo Tang; Shumei Wang; Bin Zhao; Wei Wang; Yuxi Zhu; Lingjing Hu; Xianquan Zhang; Shaoquan Xiong
Journal:  Med Sci Monit       Date:  2019-11-09

Review 4.  The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma.

Authors:  Pradeep Kumar Rajan; Utibe-Abasi Udoh; Juan D Sanabria; Moumita Banerjee; Gary Smith; Mathew Steven Schade; Jacqueline Sanabria; Komal Sodhi; Sandrine Pierre; Zijian Xie; Joseph I Shapiro; Juan Sanabria
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

5.  Comprehensive analysis of histone deacetylases genes in the prognosis and immune infiltration of glioma patients.

Authors:  Lin Shen; Yanyan Li; Na Li; Liangfang Shen; Zhanzhan Li
Journal:  Aging (Albany NY)       Date:  2022-05-11       Impact factor: 5.955

6.  The Potential Mechanism of HDAC1-Catalyzed Histone Crotonylation of Caspase-1 in Nonsmall Cell Lung Cancer.

Authors:  Chuan Jiang; Jiangrong Liao; Fang Yang; Ting Jiang; Dan Zhang; Yuanjun Xin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-02       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.